Evidence map›Paper›PMID 34502529›Full record

ArticleInternational journal of molecular sciences2021

Novel Nitrogen-Based Chalcone Analogs Provoke Substantial Apoptosis in HER2-Positive Human Breast Cancer Cells via JNK and ERK1/ERK2 Signaling Pathways.

Balsam Rizeq, Ishita Gupta, Hadeel Kheraldine, Dana Elkhalifa, Halema F Al-Farsi, Ala-Eddin Al Moustafa, Ashraf Khalil

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Balsam RizeqCollege of Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar.ORCID 0000-0001-5859-3804
Ishita GuptaCollege of Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar.ORCID 0000-0002-8627-3186
Hadeel KheraldineCollege of Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar.
Dana ElkhalifaDepartment of Pharmacy, Aspetar Orthopedic and Sports Medicine Hospital, Doha P.O. Box 2713, Qatar.
Halema F Al-FarsiCollege of Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar.
Ala-Eddin Al MoustafaCollege of Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar.ORCID 0000-0003-4452-3439
Ashraf KhalilBiomedical and Pharmaceutical Research Unit, QU Health, Qatar University, Doha P.O. Box 2713, Qatar.

Funding

Qatar University QUCG-CPH-20/21-4, QUCP-CMED-2019-1 and QUHI-CMED-19/20-1
6 · The paper itself

Abstract

Natural chalcones possess antitumor properties and play a role as inducers of apoptosis, antioxidants and cytotoxic compounds. We recently reported that novel nitrogen chalcone-based compounds, which were generated in our lab, have specific effects on triple-negative breast cancer cells. However, the outcome of these two new compounds on human epidermal growth factor receptor 2 (HER2)-positive breast cancer remains nascent. Thus, we herein investigated the effects of these compounds (DK-13 and DK-14) on two HER2-positive breast cancer cell lines, SKBR3 and ZR75. Our data revealed that these compounds inhibit cell proliferation, deregulate cell-cycle progression and significantly induce cell apoptosis in both cell lines. Furthermore, the two chalcone compounds cause a significant reduction in the cell invasion ability of SKBR3 and ZR75 cancer cells. In parallel, we found that DK-13 and DK-14 inhibit colony formation of both cell lines in comparison to their matched controls. On the other hand, we noticed that these two compounds can inhibit angiogenesis in the chorioallantoic membrane model. The molecular pathway analysis of chalcone compounds exposed cells revealed that these compounds inhibit the expression of both JNK1/2/3 and ERK1/2, the major plausible molecular pathways behind these events. Our findings implicate that DK-13 and DK-14 possess effective chemotherapeutic outcomes against HER2-positive breast cancer via the ERK1/2 and JNK1/2/3 signaling pathways.

Indexed as

ApoptosisBreast NeoplasmsCell CycleCell Line, TumorCell MovementCells, CulturedCell SurvivalChalconesErb-b2 Receptor Tyrosine KinasesHumansJNK Mitogen-Activated Protein KinasesMAP Kinase Signaling SystemMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3NitrogenChalconesErb-b2 Receptor Tyrosine KinasesJNK Mitogen-Activated Protein KinasesMAPK1 protein, humanMAPK3 protein, humanMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Nitrogenapoptosisbreast cancerchalconeschemopreventionHER2-positive

Identifiers

PMID34502529
PMCPMC8431802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.